Deepali Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 22-12-2024
- Paid Up Capital ₹ 2.50 M
as on 22-12-2024
- Company Age 23 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.85 M
as on 22-12-2024
- Satisfied Charges ₹ 0.90 M
as on 22-12-2024
- Revenue %
(FY 2022)
- Profit -11426.83%
(FY 2022)
- Ebitda -11426.83%
(FY 2022)
- Net Worth -0.60%
(FY 2022)
- Total Assets -0.00%
(FY 2022)
About Deepali Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.85 M. The company has closed loans amounting to ₹0.90 M, as per Ministry of Corporate Affairs (MCA) records.
Megha Agarwal and Nalin Agarwal serve as directors at the Company.
- CIN/LLPIN
U24232UP2001PTC026345
- Company No.
026345
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Nov 2001
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Muzaffarnagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Deepali Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Megha Agarwal  | Director | 14-Jul-2020 | Current |
| Nalin Agarwal | Director | 12-Oct-2010 | Current |
Financial Performance of Deepali Pharmaceuticals.
Deepali Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 11426.83% decrease in profit. The company's net worth dipped by a decrease of 0.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Deepali Pharmaceuticals?
In 2020, Deepali Pharmaceuticals had a promoter holding of 8.00% and a public holding of 92.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sav Pharmaceuticals LimitedActive 27 years 2 months
Megha Agarwal and Nalin Agarwal are mutual person
- J. R. Healthcare Private LimitedActive 11 years 11 months
Megha Agarwal and Nalin Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Allahabad Bank Creation Date: 24 Mar 2015 | ₹1.85 M | Open |
Punjab National Bank Creation Date: 17 Mar 2009 | ₹0.40 M | Satisfied |
Punjab National Bank Creation Date: 22 Oct 2003 | ₹0.50 M | Satisfied |
How Many Employees Work at Deepali Pharmaceuticals?
Unlock and access historical data on people associated with Deepali Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Deepali Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Deepali Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
